Gujarat, India

Ravishankara Madavati Nagaraja

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 13.0

ph-index = 2

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Innovations by Ravishankara Madavati Nagaraja

Introduction

Ravishankara Madavati Nagaraja is a prominent inventor based in Gujarat, India. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel therapeutic agents. With a total of six patents to his name, his work focuses on improving treatment options for diabetes and obesity.

Latest Patents

His latest patents include innovative Glucagon-like Peptide-1 (GLP-1) analogues. These analogues feature an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are recognized as potent GLP-1 agonists, exhibiting reduced adverse effects and improved duration of action. Furthermore, the disclosure relates to acylated derivatives of these analogs, which demonstrate enhanced potency and duration of action, making them suitable for oral administration. These advancements may provide valuable treatment options for individuals suffering from diabetes and obesity.

Career Highlights

Ravishankara is currently associated with Sun Pharmaceutical Industries Limited, a leading global pharmaceutical company. His work at this organization has allowed him to focus on innovative research and development in the pharmaceutical sector.

Collaborations

He has collaborated with notable colleagues, including Rajamannar Thennati and Nishith C Chaturvedi, to further advance his research and innovations.

Conclusion

Ravishankara Madavati Nagaraja's contributions to the field of pharmaceuticals through his innovative patents highlight his commitment to improving healthcare solutions. His work continues to pave the way for advancements in the treatment of diabetes and obesity.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…